Line 32: | Line 32: | ||
<h4><br>Rheumatoid arthritis (RA) is a serious chronic, inflammatory and systemic autoimmune disease. | <h4><br>Rheumatoid arthritis (RA) is a serious chronic, inflammatory and systemic autoimmune disease. | ||
<br>It is of great essence to develop a kind of novel cell-targeted therapy for RA because there is no radical cure | <br>It is of great essence to develop a kind of novel cell-targeted therapy for RA because there is no radical cure | ||
− | for RA for the time being. | + | for RA for the time being. To solve the problems existing in the current treatment of RA, we design and build a brand new immunotherapy. FOXP3+ regulatory T cells(Tregs), which can suppress and regulate immune reactions, are modified utilizing a lentiviral vector system to express a chimeric antigen receptor(CAR) targeting inflammatory cells associated with RA. |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
<br>Meanwhile, we insert the Syn-Notch receptor to activate the functional stability pathway of Tregs in the | <br>Meanwhile, we insert the Syn-Notch receptor to activate the functional stability pathway of Tregs in the | ||
inflammatory environment, which enables them to play their role of immunosuppression in lesions more | inflammatory environment, which enables them to play their role of immunosuppression in lesions more | ||
− | efficiently and more stably. | + | efficiently and more stably. These two redirections of the two different but interrelated systems on Tregs ensure this novel therapy a promising anti-RA effect. </h4> |
− | + | ||
− | + | ||
</div> | </div> | ||
</div> | </div> |
Revision as of 10:50, 1 November 2017
Our HEAD-Treg
Description